A Pathologists Perspective: Exploring the Expanded Clinical Utility of HER2 IHC Scoring in Metastatic Breast Cancer
Wednesday, May 21, 2025, 12:00 PM–1:00 PM ET
Webinar presenter Pranil K. Chandra, DO, Senior Vice President, Chief Medical Officer, PathGroup, discusses the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer.
What will this webinar empower you to do?
- Understand the clinical significance of identifying patients with certain low levels
of HER2 in metastatic breast cancer. - Understand the evolution of the HER2 spectrum.
- Highlight key considerations that impact HER2 IHC scoring and interpretation.
- Review guidance for pathologists to accurately report HER2 status.
- Ask questions of our distinguished presenter.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within.
This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation. In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company sponsored programs. Please be advised that information such as your name and the value and purpose of any educational item, meal, or other items of value you may receive may be publicly disclosed. If you are licensed in any state or other jurisdiction, or are an employee or contractor of any organization or governmental entity that limits or prohibits meals from pharmaceutical companies, please identify yourself so that compliance with such requirements can be ensured. PP-US-8201a-2374 04/25
Shifting HERizons: Navigating the Evolving Landscape of HER2 in Breast Carcinoma
Tuesday, June 10, 2025, 1:00 PM–2:00 PM ET
Webinar presenter Raza Hoda, MD, Staff Pathologist, Cleveland Clinic, Assistant Professor of Pathology, Cleveland Clinic Lerner College of Medicine, discusses the importance of advancements in HER2 testing, including HER2 Ultra Low.
What will you learn from this webinar?
- Review the role of HER2 in breast carcinoma, including its biological significance and impact on treatment decisions.
- Trace the evolution of HER2-targeted therapy and its influence on patient outcomes.
- Examine the progression of HER2 testing guidelines and their implications
for clinical practice. - Discuss HER2 Low, Ultralow, and Null categories, and interpret their emerging
clinical relevance. - Identify key diagnostic challenges in HER2 IHC interpretation and apply best
practices to overcome them.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within.
The webinar is made possible by a special educational grant from Roche.
Amplicon-based NGS panels
in clinical practice: From broad oncology applications to advancing breast cancer care
Tuesday, June 17, 2025, 1:00 PM–2:00 PM ET
Webinar presenters Emilie Lalonde, PhD, FACMG, Molecular Geneticist and Cytogeneticist,
Molecular Diagnostics Division, PaLM, London Health Sciences Centre and St. Joseph’s Health Care, Assistant Professor, Pathology and Laboratory Medicine, Western University, and Cheryl A. Mather, MD Medical Director, Molecular Pathology (North Sector), Alberta Precision Laboratories
Assistant Clinical Professor, Department of Laboratory Medicine & Pathology, University of Alberta, discuss how amplicon-based NGS panels meet biomarker testing guidelines in practice including routine diagnostics, expanded workup, and copy number variation (CNV) detection.
What will this webinar empower you to do?
- Learn how amplicon-based NGS assays can be utilized to help manage patient treatment decisions.
- Engage with experienced customers specializing in routine diagnostics and breast cancer biomarker testing.
- Participate in an interactive Q&A with our distinguished speakers.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within.
The webinar is made possible by a special educational grant from Thermo Fisher Scientific.
Expression of HER2 at the Lower End of the Spectrum in Breast Cancer: IHC Testing, Challenges in Scoring, and Optimal Reporting Practices
Monday, June 23, 2025, 1:00 PM–2:00 PM ET
Webinar presenters Frédérique Penault-Llorca, MD, PhD, General Director, Jean Perrin Center, Professor of Pathology, University of Clermont-Ferrand, France, and Ana Garrido-Castro, MD Breast Oncologist, Dana-Farber Cancer Institute
Assistant Professor, Harvard Medical School, Boston, Massachusetts, discuss strategies for optimizing HER2 IHC testing and reporting, as well as best-practices for overcoming challenges associated with HER2 IHC scoring, especially for lower expression of HER2.
What will this webinar empower you to do?
- Improve awareness on the evolution of the HER2 spectrum.
- Reinforce understanding of the value of careful validated assay selection to
accurately identify patients with lower expression of HER2 - Highlight key considerations that impact optimal HER2 IHC scoring, interpretation, and reporting
- Address common questions associated with HER2 IHC scoring, interpretation,
and validation
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within.
This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation. PP-US-8201a-2382 04/25